This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.
Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.

 

This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.

Are you a healthcare professional?

Stephen
Harrison
Pinnacle Clinical Research Austin, Texas, USA

Stephen Harrison earned his medical degree from the University of Mississippi School of Medicine, Jackson, Mississippi, USA. He completed his internal medicine residency and gastroenterology fellowship at Brooke Army Medical Center, Houston, Texas, USA and a fourth-year advanced liver disease fellowship at Saint Louis University, St. Louis, Missouri, USA.

 

He is board certified in both Internal Medicine and Gastroenterology. Dr Harrison is currently a Visiting Professor of Hepatology at the Radcliffe Department of Medicine, University of Oxford, Oxford, UK. He is internationally known for studies in hepatitis C and non-alcoholic fatty liver disease with more than 200 peer-reviewed publications in these fields. Currently, Dr Harrison currently serves as the Medical Director for Pinnacle Clinical Research and the President of Summit Clinical Research.

properties.alt

Vincent Wai-Sun Wong

The Chinese University of Hong Kong, Hong Kong, China


Vincent Wong is a professor and head of the Division of Gastroenterology and Hepatology, The Chinese University of Hong Kong, China. He graduated from the same university and received his specialist training under Professor Joseph Sung and Professor Henry Chan at the Prince of Wales Hospital, Hong Kong.

 

Professor Wong’s research focuses on viral hepatitis and non-alcoholic fatty liver disease (NAFLD), in particular the use of non-invasive tests for screening and diagnosis. He has more than 400 publications in international medical journals, and his latest h-index is 82. Together with the Asia-Pacific Working Party, Professor Wong wrote the Asia-Pacific Guidelines on the Management of NAFLD in 2018. He is an associate editor of Clinical Gastroenterology and Hepatology and an editorial board member of the Journal of Hepatology, Hepatology, and Alimentary Pharmacology & Therapeutics. Professor Wong served as the president of the Hong Kong Association for the Study of Liver Diseases from 2015 to 2017. He has received research awards from the Asian Pacific Association for the Study of the Liver, Asian Pacific Digestive Week Federation, British Society of Gastroenterology, Hong Kong College of Physicians and the Food and Health Bureau. Professor Wong is a fellow of the Royal College of Physicians of London, Royal College of Physicians of Edinburgh, Hong Kong College of Physicians and Hong Kong Academy of Medicine.


Read full bio
properties.alt

Elisabetta Bugianesi

University Hospital ‘Città della Salute e della Scienza’, Turin, Italy


Elisabetta Bugianesi is a practising hepatologist based at the Gastroenterology Division of the University Hospital ‘Città della Salute e della Scienza’ in Turin, Italy. She is Head of the Gastrohepatology Laboratory and the Lead Physician for the Hepatology Outpatient Clinic (with approximately 1500 patients/year). Professor Bugianesi has over 15 years of experience in the field of non-alcoholic fatty liver disease (NAFLD) as a clinical researcher.

 

Professor Bugianesi’s work has made a particular impact in describing metabolic mechanisms of insulin resistance related to the onset and progression of liver damage. She has driven research on the natural history of NAFLD (including the first demonstration of hepatocellular carcinoma as a complication of non-alcoholic steatohepatitis-related liver disease) and the development of non-invasive markers of fibrosis, including the NAFLD fibrosis score. Professor Bugianesi was Principal Investigator of the Seventh Framework Programme (FP7)-funded Fatty Liver: Inhibition of Progression (FLIP) consortium and is currently Principal Investigator in two other major research consortia: Elucidating Pathways of Steatohepatitis (EPoS) and Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS).

 

Professor Bugianesi is a member of the Lancet-EASL Commission for Liver Disease in Europe and Associate Editor of the Journal of Hepatology.


Read full bio